The results do not show a significant change in the trend of the year, which had already been covered after 1Q25 results , at which pointLong-only investment, evaluating companies from an operational, buy-and-hold perspective.Quipus Capital does not focus on market-driven dynamics and future price action. Instead, our articles focus on operational aspects, understanding the long-term earnings power of companies, the competitive dynamics of the industries where they participate, and buying companies that we ...

Financial Data and Key Metrics Changes - Company reported a revenue growth of 15% year-over-year, reaching $1,856 million for the first half of 2025 [4] - Adjusted EBITDA increased by 20% year-over-year, totaling $893 million, with a margin of 48.1%, up 220 basis points from the previous year [4][17] - Basic EPS rose to 4.69, representing a 17% increase compared to the previous year [4] Business Line Data and Key Metrics Changes - Undergraduate segment revenue grew over 16%, totaling R$1,642 million, with a 14% increase in the number of medical students [10] - Continuing education revenue increased by 8% year-over-year, reaching R$138 million, driven by a 12% growth in graduate journey students [11] - Medical practice solutions segment saw a revenue growth of over 9%, reaching R$84 million, with B2P revenues up nearly 12% [12][13] Market Data and Key Metrics Changes - The ecosystem reached 302,000 active users, indicating strong engagement among physicians and medical students across Brazil [14] - The number of approved medical seats increased to 3,653, reflecting a 14% growth year-over-year [10] Company Strategy and Development Direction - Company remains focused on operational excellence, aiming for robust growth, increased profitability, and solid cash generation as strategic pillars for long-term value creation [3] - A new share repurchase program was approved, allowing the company to buy back up to 4 million Class A shares by the end of 2026, reflecting a commitment to shareholder value [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting full-year 2025 guidance, supported by strong business fundamentals and disciplined execution [4] - The competitive landscape for medical education is expected to be more intense in the second half of the year, but the company is optimistic about maintaining occupancy rates [45] Other Important Information - The company is actively addressing the implications of new tax legislation aligned with OECD Pillar Two rules, with ongoing legal and administrative efforts to challenge the tax charge [52][53] Q&A Session Summary Question: What are the main levers for profitability expansion in the quarter? - Management highlighted improved efficiency in SG&A expenses and centralization of services as key factors contributing to margin expansion [22][24] Question: Can you provide insights on the EBITDA guidance for the second half? - Management prefers to remain conservative due to seasonality in continuing education, despite strong performance in the first half [35][36] Question: What is the competitive outlook for the second half intake? - Management noted increased competition due to new approvals of medical seats and a reduced candidate ratio, but expressed confidence in maintaining occupancy [44][45] Question: What are the implications of the new taxation? - Management is pursuing both legal and administrative avenues to challenge the new tax legislation, emphasizing its impact on the ProUni program [52][53] Question: How is the M&A environment perceived? - Management indicated that they are looking for the right opportunities at favorable prices, with a focus on good locations and reputations [58][61] Question: What is the strategy behind the share buyback program? - Management explained that the buyback program aims to enhance shareholder value while considering liquidity impacts [62][64]

Financial Performance - Revenue reached R$1,855.8 million, a 15.0% year-over-year increase[7] - Adjusted EBITDA was R$892.8 million, up 20.4% year-over-year, with an adjusted EBITDA margin of 48.1%, a 220 bps increase[7] - Net income increased by 17.0% year-over-year to R$433.6 million, with earnings per share at R$4.69, a 16.9% increase[7] - Cash flow from operating activities increased by 14.6% year-over-year to R$783.0 million[7] Operational Highlights - Medical school students increased by 14% to 25,733[9, 7] - Continuing education revenue increased by 7.9% year-over-year to R$137.5 million[7, 19] - Medical Practice Solutions revenue increased by 9.3% year-over-year to R$84.0 million[7, 22] - The number of users in Afya's ecosystem positively impacted reached 302,000[7, 25] Capital Allocation - Afya's board approved a new share repurchase program of up to 4 million Class A shares[12] Regulatory Impact - Brazil adopted OECD Pillar Two rules, potentially increasing the effective tax rate to a 15% global minimum, with an additional income tax expense of R$56.6 million for the six-month period ended in June 2025[42, 45]

Group 1: Primoris Services (PRIM) - Primoris Services operates as one of the largest specialty contractors and infrastructure companies in the United States [1] - The company carries a Zacks Rank 1 (Strong Buy) [1] - The Zacks Consensus Estimate for its current year earnings has increased by 0.9% over the last 60 days [1] - Primoris has a PEG ratio of 1.57 compared to 3.83 for the industry [2] - The company possesses a Growth Score of A [2] Group 2: Afya (AFYA) - Afya is a medical education group primarily in Brazil [2] - The company carries a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings has increased by 4.6% over the last 60 days [2] - Afya has a PEG ratio of 0.47 compared to 0.82 for the industry [2] - The company possesses a Growth Score of B [2] Group 3: Jabil (JBL) - Jabil is one of the largest global suppliers of electronic manufacturing services [3] - The company carries a Zacks Rank 1 [3] - The Zacks Consensus Estimate for its current year earnings has increased by 5.2% over the last 60 days [3] - Jabil has a PEG ratio of 1.41 compared to 1.95 for the industry [3] - The company possesses a Growth Score of B [3]

Core Insights - Investors in the Schools sector may consider Afya (AFYA) and Grand Canyon Education (LOPE) as potential investment opportunities [1] - The Zacks Rank system, which emphasizes positive earnings estimate revisions, is a key tool for identifying value opportunities [2] Valuation Metrics - Afya has a Zacks Rank of 1 (Strong Buy), while Grand Canyon Education has a Zacks Rank of 3 (Hold), indicating a stronger earnings outlook for AFYA [3] - AFYA's forward P/E ratio is 10.16, significantly lower than LOPE's forward P/E of 20.16, suggesting AFYA may be undervalued [5] - The PEG ratio for AFYA is 0.55, compared to LOPE's PEG ratio of 1.34, indicating better expected earnings growth relative to its price [5] - AFYA's P/B ratio is 2.02, while LOPE's P/B ratio is 6.42, further highlighting AFYA's relative valuation advantage [6] - Based on these metrics, AFYA holds a Value grade of A, while LOPE has a Value grade of C, making AFYA the more attractive option for value investors [6]

Core Insights - Afya (AFYA) currently holds a Zacks Rank of 1 (Strong Buy), indicating a more favorable earnings estimate revision trend compared to K12 (LRN), which has a Zacks Rank of 2 (Buy) [3] - Value investors typically assess various fundamental metrics to identify undervalued stocks, beyond just earnings estimates [3][4] Valuation Metrics - AFYA has a forward P/E ratio of 10.86, significantly lower than LRN's forward P/E of 20.74, suggesting AFYA may be undervalued [5] - The PEG ratio for AFYA is 0.58, while LRN's PEG ratio is 1.04, indicating AFYA's expected earnings growth is more favorable relative to its price [5] - AFYA's P/B ratio stands at 2.16, compared to LRN's P/B of 4.52, further supporting the notion that AFYA is a better value option [6] - Overall, AFYA's Value grade is A, while LRN's Value grade is C, highlighting AFYA's superior valuation metrics and earnings outlook [6]

Company Performance - Afya (AFYA) has returned 8.5% year-to-date, outperforming the average gain of 5.3% in the Consumer Discretionary sector [4] - The Zacks Consensus Estimate for Afya's full-year earnings has increased by 8.2% over the past three months, indicating improved analyst sentiment and a stronger earnings outlook [4] Industry Context - Afya is part of the Schools industry, which consists of 17 companies and currently ranks 19 in the Zacks Industry Rank [6] - The Schools industry has gained an average of 2.8% so far this year, showing that Afya is performing better than its industry peers [6] Sector Ranking - The Consumer Discretionary group is ranked 10 within the Zacks Sector Rank, which evaluates 16 different sector groups [2] - Afya holds a Zacks Rank of 1 (Strong Buy), indicating a favorable outlook compared to other stocks in the sector [3]

Core Viewpoint - The article emphasizes the importance of value investing and highlights specific companies, Afya (AFYA) and American Public Education (APEI), as strong value stock opportunities based on their financial metrics and rankings [2][4][7]. Company Analysis: Afya (AFYA) - Afya (AFYA) holds a Zacks Rank of 1 (Strong Buy) and a Value grade of A, indicating strong potential for value investors [4]. - The stock has a P/E ratio of 11.03, significantly lower than the industry average of 15.82, suggesting it may be undervalued [4]. - AFYA's Forward P/E has fluctuated between 7.81 and 12.39 over the past year, with a median of 9.41 [4]. - The PEG ratio for AFYA is 0.59, compared to the industry average of 0.72, indicating favorable growth expectations relative to its price [5]. - AFYA's P/B ratio stands at 2.27, lower than the industry average of 3.38, further supporting its valuation as attractive [6]. Company Analysis: American Public Education (APEI) - American Public Education (APEI) has a Zacks Rank of 2 (Buy) and a Value score of A, making it another appealing option for value investors [7]. - APEI's Forward P/E ratio is 17.26, which is higher than the industry average of 15.82, suggesting a different valuation perspective [7]. - The PEG ratio for APEI is 1.15, indicating it may be priced higher relative to its growth expectations compared to the industry average of 0.72 [7]. - APEI's P/B ratio is 1.95, also lower than the industry average of 3.38, indicating it may be undervalued [8]. Summary of Valuation Metrics - Both AFYA and APEI exhibit strong value metrics, suggesting they are likely undervalued in the current market [9]. - The analysis of earnings outlook and valuation ratios positions AFYA and APEI as impressive value stocks at this time [9].

Group 1 - Dundee Precious Metals (DPMLF) has seen a 46.2% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Eldorado Gold (EGO) has experienced a 13% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Afya (AFYA) has recorded an 8.8% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] Group 2 - Allison Transmission Holdings (ALSN) has seen a 6.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3] - Horace Mann Educators (HMN) has experienced a 5.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]

Group 1 - Afya Limited (NASDAQ: AFYA) reported 1Q25 earnings that were approximately in line with expectations and seasonal trends [1] - The company experienced significant growth due to the integration of a large acquisition, Unidompedro, from the previous year [1] - The investment strategy focuses on operational aspects and long-term earnings potential rather than market-driven dynamics [1] Group 2 - The analysis emphasizes a long-only investment approach, suggesting that only a small fraction of companies should be considered for purchase at any given time [1] - Hold articles are intended to provide valuable information for future investors and introduce a healthy skepticism in a bullish market [1]